A Study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of SNDX-5613 when given
in combination with 2 different chemotherapy regimens in participants with
relapsed/refractory leukemias harboring lysine methyltransferase 2A (KMT2A) or mNPM1.